CEO Joseph Ciaffoni steps down; Chairman Michael Heffernan named Interim CEO

COLLEGIUM PHARMACEUTICAL, INC

Joseph Ciaffoni to step down as President and CEO effective May 24, 2024.
Ciaffoni will not stand for re-election to the Board at May 16 Annual Meeting; Board reduced from nine to eight.
Michael Heffernan, current Chairman, appointed Interim President and CEO effective May 24, 2024.
Heffernan to receive base salary at $291,666 annual rate (one-third of Ciaffoni's salary).
Board has initiated a search for a permanent President and CEO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Ciaffoni

President and Chief Executive Officer

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-05-24
Successor: Michael Heffernan
Filed: May 10, 2024, 7:59 PM ET

announced that Joseph Ciaffoni will step down as the President and Chief Executive Officer of Collegium Pharmaceutical, Inc. (the “Company”) effective May 24, 2024.

Appointed (interim)

Michael Heffernan

Interim President and Chief Executive Officer

COLL · COLLEGIUM PHARMACEUTICAL, INC

Effective: 2024-05-24
Filed: May 10, 2024, 7:59 PM ET

the Board approved the appointment of Michael Heffernan, the Company’s Chairman of the Board, to Interim President and Chief Executive Officer, effective May 24, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Ciaffoni departed as President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

announced that Joseph Ciaffoni will step down as the President and Chief Executive Officer of Collegium Pharmaceutical, Inc. (the “Company”) effective May 24, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Heffernan was appointed as Interim President and Chief Executive Officer at COLLEGIUM PHARMACEUTICAL, INC.

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

the Board approved the appointment of Michael Heffernan, the Company’s Chairman of the Board, to Interim President and Chief Executive Officer, effective May 24, 2024

View on SEC.gov

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001104659-24-059656

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.